SensoLyte® 520 Factor Xa Assay Kit

Produktnummer ABIN1882459

Kurzübersicht für SensoLyte® 520 Factor Xa Assay Kit (ABIN1882459)

Target: Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

Nachweismethode: Fluorometric

Applikation: Fluorescence Resonance Energy Transfer Microscopy (FRET)

Produktdetails

Marke: SensoLyte®

Produktmerkmale: The SensoLyte® 520 Factor Xa Assay Kit provides a convenient assay for high throughput screening of FXa inhibitors or continuous assay of enzyme activity. It detects FXa activity using a 5-FAM/QXL™ 520 fluorescence resonance energy transfer (FRET) peptide. In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. Upon cleavage into two separate fragments by FXa, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission wavelengths = 490 nm/520 nm. With excellent fluorescence quantum yield and longer wavelength, 5-FAM shows less interference from autofluorescence of test compounds and cellular components. The assays are performed in a convenient 96-well microplate format.

Anwendungsinformationen

Kommentare:

FRET-based Assay Kit

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Handhabung: Protect Components A and B from light and moisture.

Lagerung: -80 °C

Informationen zur Lagerung: Store all kit components at -20 °C, except for Component C. Store Component C at -80 °C. Component D can be stored at room temperature for convenience

Antigendetails

Target: Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

Andere Bezeichnung: Factor Xa

Hintergrund: Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex. FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation. In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets. FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.